Trevi Therapeutics, Inc. (TRVI) Free cash flow 2018–2025
Trevi Therapeutics, Inc. (TRVI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$42.1MFY2025 · since FY2018: -$18.4M → -$42.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$42.1M | -10.0% |
| FY2024 | -$38.3M | -20.2% |
| FY2023 | -$31.8M | -12.4% |
| FY2022 | -$28.3M | — |
| FY2020 | -$29.0M | -25.7% |
| FY2019 | -$23.1M | -25.2% |
| FY2018 | -$18.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TRVI financial trends
TRVI RevenueTRVI Net incomeTRVI Net marginTRVI Gross profitTRVI Gross marginTRVI Operating incomeTRVI Operating marginTRVI Operating cash flowTRVI Capital expendituresTRVI Return on equityTRVI Stock buybacksTRVI Dividends paidTRVI Total assetsTRVI Total liabilitiesTRVI Shareholders’ equityTRVI overview →